h2o Therapeutics, a digital health company that develops AI, augmented reality and mobile-based therapeutics, is partnering with global healthcare company AmerisourceBergen to commercialize its Parkinson’s disease-focused offering dubbed Parky.
Parky, which received 510(k) clearance last year, is a prescription mobile app that utilizes the Apple Watch to monitor an individual’s Parkinson’s disease symptoms, such as tremors and dyskinesia, or uncontrolled, involuntary body movement.
The app also includes medication reminders and a portal for healthcare providers to track an individual’s symptoms.
As part of the collaboration, AmerisourceBergen will support Parky’s integration within health systems and facilitate patient engagement through its DTx Connect platform, which allows for ordering, dispensing and fulfilling physician-ordered digital therapeutics and diagnostics.
“Following the recent FDA clearance, we continue to focus on strategies and solutions that will enable us to expand patient access to Parky,” Yagmur Selin Gulmus, founder of h2o Therapeutics, said in a statement. “Through this arrangement with AmerisourceBergen, our goal is to reduce barriers along the patient journey, improve access and expand our commercial reach.”
THE LARGER TREND
Other digital health companies have used Apple’s Movement Disorder API to track Parkinson’s disease symptoms.
Digital health technology company NeuroRPM received FDA 510(k) clearance for its AI-enabled remote monitoring app that utilizes an Apple Watch to track Parkinson’s symptoms such as bradykinesia, tremor and dyskinesia.